Feifei Na

Dr. Feifei Na


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
JCJingyao Chen
Jingyao Chen
LZLei Zhao
Lei Zhao
HPHongling Peng
Hongling Peng
SDSiqi Dai
Siqi Dai
YQYuan Quan
Yuan Quan
FNFeifei Na
Feifei Na

18 November 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
BFBaijie Feng
Baijie Feng
YZYue Zheng
Yue Zheng
JZJiayuan Zhang
Jiayuan Zhang
MTMin Tang
Min Tang
FNFeifei Na
Feifei Na

8 December 2022 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
JCJingyao Chen
Jingyao Chen
FNFeifei Na
Feifei Na
The prevalency of lung disease has increased worldwide, especially in the aging population. It is essential to develop novel disease models, that are superior to traditional models. Organoids are three-dimensional (3D) in vitro structures that produce from self-organizing and differentiating stem cells, including pluripotent stem cells (PSCs) or adult stem cells (ASCs). They can recapitulate the in vivo cellular heterogeneity, genetic characteristics, structure, and functionality of original tissues. Drug responses of patient-derived organoids (PDOs) are consistent with that of patients, and show correlations with genetic alterations. Thus, organoids have proven to be valuable in studying the biology of disease, testing preclinical drugs and developing novel therapies. In recent years, organoids have been successfully applied in studies of a variety of lung diseases, such as lung cancer, influenza, cystic fibrosis, idiopathic pulmonary fibrosis, and the recent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. In this review, we provide an update on the generation of organoid models for these diseases and their applications in basic and translational research, highlighting these signs of progress in pathogenesis study, drug screening, personalized medicine and immunotherapy. We also discuss the current limitations and future perspectives in organoid models of lung diseases.

7 May 2026 in Cell
Verified
Journal Article
Closed access
YWYiyun Wang
Yiyun Wang
AZAiling Zhong
Ailing Zhong
BWBo Wang
Bo Wang
XZXiaoqian Zhai
Xiaoqian Zhai
CLChang Lei
Chang Lei
CCChong Chen
Chong Chen

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMengsha Zhang
Mengsha Zhang
AZAiling Zhong
Ailing Zhong
HLHongyu Liu
Hongyu Liu
LZLei Zhao
Lei Zhao
YWYingjie Wang
Yingjie Wang
CCChong Chen
Chong Chen
Gastric Squamous Cell Carcinoma (GSCC) is a rare but aggressive subtype of gastric cancer with unique histopathology, whose etiology remains poorly understood. Here, we perform genomics analyses of twenty GSCC samples and find that epigenetic regulation genes are among the most frequently mutated genes, including Enhancer of zeste homolog 2 (EZH2). Ezh2 loss induces squamous feature both in gastric organoids in vitro and in vivo mouse model. Ezh2 deficiency, together with Trp53 and Pten loss, both of which are also frequently mutated in GSCC, give rise to full-blown GSCC in mice. Mechanistically, we find that Ezh2 could repress the expression of Transcription factor AP-2 gamma (Tfap2c), a transcription factor with the ability to initiate epidermal squamous differentiation, through H3K27 methylation. Disruption of Tfap2c reduces the squamous characteristics of the Ezh2 loss-driven GSCC and reverses its resistance to chemo treatment. Our findings elucidate key molecular mechanisms underlying GSCC pathogenesis and identify potential therapeutic targets for this aggressive malignancy.

14 October 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
HYHua You
Hua You
MFMingyu Fan
Mingyu Fan
LYLimei Yin
Limei Yin
FNFeifei Na
Feifei Na
LYLiting You
Liting You
This study delves into the landscape of RNA modification (RM)-related long non-coding RNAs (lncRNAs) within non-small cell lung cancer (NSCLC). We aim to uncover their significance in cancer biology and potential clinical implications. We utilized diverse datasets to identify 444 RM-related genes with 12 RMs. RM scores were computed, and associations with survival were analyzed. Weighted gene co-expression network analysis identified 730 RM-related lncRNAs. Univariate Cox regression identified 63 prognostically significant lncRNAs, leading to the classification of NSCLC samples into two clusters. Distinct differences in overall survival and disease-free interval were observed between the identified lncRNA clusters, showcasing their prognostic relevance. Molecular characterization uncovered mutation landscape variations, with cluster 2 displaying higher mutation rates in TP53 and TTN. Cluster-specific genomic alterations, immune cell infiltration, and immune checkpoint gene expression patterns were identified. Drug sensitivity analysis revealed distinct profiles, with cluster 1 showing potential resistance to a combined approach of certain chemotherapy and immunotherapy, while cluster 2 may be suitable for monotherapy with specific chemotherapeutic or targeted agents. In conclusion, this study stands as the first and most comprehensive exploration, elucidating the intricate connections between RM, lncRNAs, NSCLC, and tumor immunity. Its findings significantly enhance our comprehension of NSCLC heterogeneity, offering pivotal insights and paving the path toward personalized treatment strategies.